Business Context and Reporting Period
Company: EyeGate Pharmaceuticals, Inc. (Note: Metadata listed "Kiora Pharmaceuticals Inc" but the filing text identifies the registrant as EyeGate Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 14, 2018
Event: Termination of Material Definitive Agreements with Bausch Health Ireland Limited and Valeant Pharmaceuticals Luxembourg S.a.r.l.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
- Agreement Termination: Bausch Health voluntarily terminated the 2015 and 2017 License Agreements effective March 14, 2019.
- Reason for Termination: The decision follows September 2018 Phase 3 trial results for the EGP-437 combination product which did not demonstrate non-inferiority for anterior uveitis.
- Strategic Shift: The Company is shifting resources to focus on its Ocular Bandage Gel (OBG) product candidate, which received positive top-line results in November 2018.
- Asset Recovery: Upon termination, the Company regains all rights to the EGP-437 product previously licensed to Bausch Health.
- Reimbursement: The Company will be reimbursed by Bausch Health for certain out-of-pocket development costs incurred under the Agreements.
Guidance, Outlook, and Risks
Outlook: Management is redirecting development efforts toward the OBG product candidate following the termination of the EGP-437 partnership.
Risks/Contingencies: The termination ends the exclusive worldwide commercial and manufacturing rights held by Bausch Health for the EGP-437 product in anterior uveitis and post-operative ocular inflammation/pain. The Company now assumes full responsibility for the EGP-437 asset.
Investor Verification Checklist
- Verify the exact amount of out-of-pocket cost reimbursement to be received from Bausch Health.
- Confirm the specific terms regarding the reversion of rights for the EGP-437 product.
- Review the detailed Phase 3 trial data for EGP-437 that led to the termination.
- Assess the timeline and regulatory status of the OBG product candidate.
- Check for any remaining financial obligations or liabilities associated with the terminated agreements.